Amending HIV Drugs

A Novel Small-Molecule Approach to Target Lupus Anti-DNA Antibodies

Sonya Vanpatten, Shan Sun, Mingzhu He, Kai Fan Cheng, Ahmad Altiti, Angelos Papatheodorou, Czeslawa Kowal, Venkatesh Jeganathan, James M. Crawford, Ona Bloom, Bruce T. Volpe, Christian Grant, Nathalie Meurice, Thomas R. Coleman, Betty Diamond, Yousef Al-Abed

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Systemic lupus erythematosus is an autoimmune disease that can affect numerous tissues and is characterized by the production of nuclear antigen-directed autoantibodies (e.g., anti-dsDNA). Using a combination of virtual and ELISA-based screens, we made the intriguing discovery that several HIV-protease inhibitors can function as decoy antigens to specifically inhibit the binding of anti-dsDNA antibodies to target antigens such as dsDNA and pentapeptide DWEYS. Computational modeling revealed that HIV-protease inhibitors comprised structural features present in DWEYS and predicted that analogues containing more flexible backbones would possess preferred binding characteristics. To address this, we reduced the internal amide backbone to improve flexibility, producing new small-molecule decoy antigens, which neutralize anti-dsDNA antibodies in vitro, in situ, and in vivo. Pharmacokinetic and SLE model studies demonstrated that peptidomimetic FISLE-412,1 a reduced HIV protease inhibitor analogue, was well-tolerated, altered serum reactivity to DWEYS, reduced glomeruli IgG deposition, preserved kidney histology, and delayed SLE onset in NZB/W F1 mice.

Original languageEnglish (US)
Pages (from-to)8859-8867
Number of pages9
JournalJournal of Medicinal Chemistry
Volume59
Issue number19
DOIs
StatePublished - Oct 13 2016

Fingerprint

HIV Protease Inhibitors
Antinuclear Antibodies
HIV
Antigens
Anti-Idiotypic Antibodies
Pharmaceutical Preparations
Peptidomimetics
Nuclear Antigens
Amides
Systemic Lupus Erythematosus
Autoantibodies
Autoimmune Diseases
Histology
Pharmacokinetics
Immunoglobulin G
Enzyme-Linked Immunosorbent Assay
Kidney
Serum

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Vanpatten, S., Sun, S., He, M., Cheng, K. F., Altiti, A., Papatheodorou, A., ... Al-Abed, Y. (2016). Amending HIV Drugs: A Novel Small-Molecule Approach to Target Lupus Anti-DNA Antibodies. Journal of Medicinal Chemistry, 59(19), 8859-8867. https://doi.org/10.1021/acs.jmedchem.6b00694

Amending HIV Drugs : A Novel Small-Molecule Approach to Target Lupus Anti-DNA Antibodies. / Vanpatten, Sonya; Sun, Shan; He, Mingzhu; Cheng, Kai Fan; Altiti, Ahmad; Papatheodorou, Angelos; Kowal, Czeslawa; Jeganathan, Venkatesh; Crawford, James M.; Bloom, Ona; Volpe, Bruce T.; Grant, Christian; Meurice, Nathalie; Coleman, Thomas R.; Diamond, Betty; Al-Abed, Yousef.

In: Journal of Medicinal Chemistry, Vol. 59, No. 19, 13.10.2016, p. 8859-8867.

Research output: Contribution to journalArticle

Vanpatten, S, Sun, S, He, M, Cheng, KF, Altiti, A, Papatheodorou, A, Kowal, C, Jeganathan, V, Crawford, JM, Bloom, O, Volpe, BT, Grant, C, Meurice, N, Coleman, TR, Diamond, B & Al-Abed, Y 2016, 'Amending HIV Drugs: A Novel Small-Molecule Approach to Target Lupus Anti-DNA Antibodies', Journal of Medicinal Chemistry, vol. 59, no. 19, pp. 8859-8867. https://doi.org/10.1021/acs.jmedchem.6b00694
Vanpatten, Sonya ; Sun, Shan ; He, Mingzhu ; Cheng, Kai Fan ; Altiti, Ahmad ; Papatheodorou, Angelos ; Kowal, Czeslawa ; Jeganathan, Venkatesh ; Crawford, James M. ; Bloom, Ona ; Volpe, Bruce T. ; Grant, Christian ; Meurice, Nathalie ; Coleman, Thomas R. ; Diamond, Betty ; Al-Abed, Yousef. / Amending HIV Drugs : A Novel Small-Molecule Approach to Target Lupus Anti-DNA Antibodies. In: Journal of Medicinal Chemistry. 2016 ; Vol. 59, No. 19. pp. 8859-8867.
@article{57d31e07d06343cca46baf8a057b4b16,
title = "Amending HIV Drugs: A Novel Small-Molecule Approach to Target Lupus Anti-DNA Antibodies",
abstract = "Systemic lupus erythematosus is an autoimmune disease that can affect numerous tissues and is characterized by the production of nuclear antigen-directed autoantibodies (e.g., anti-dsDNA). Using a combination of virtual and ELISA-based screens, we made the intriguing discovery that several HIV-protease inhibitors can function as decoy antigens to specifically inhibit the binding of anti-dsDNA antibodies to target antigens such as dsDNA and pentapeptide DWEYS. Computational modeling revealed that HIV-protease inhibitors comprised structural features present in DWEYS and predicted that analogues containing more flexible backbones would possess preferred binding characteristics. To address this, we reduced the internal amide backbone to improve flexibility, producing new small-molecule decoy antigens, which neutralize anti-dsDNA antibodies in vitro, in situ, and in vivo. Pharmacokinetic and SLE model studies demonstrated that peptidomimetic FISLE-412,1 a reduced HIV protease inhibitor analogue, was well-tolerated, altered serum reactivity to DWEYS, reduced glomeruli IgG deposition, preserved kidney histology, and delayed SLE onset in NZB/W F1 mice.",
author = "Sonya Vanpatten and Shan Sun and Mingzhu He and Cheng, {Kai Fan} and Ahmad Altiti and Angelos Papatheodorou and Czeslawa Kowal and Venkatesh Jeganathan and Crawford, {James M.} and Ona Bloom and Volpe, {Bruce T.} and Christian Grant and Nathalie Meurice and Coleman, {Thomas R.} and Betty Diamond and Yousef Al-Abed",
year = "2016",
month = "10",
day = "13",
doi = "10.1021/acs.jmedchem.6b00694",
language = "English (US)",
volume = "59",
pages = "8859--8867",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "19",

}

TY - JOUR

T1 - Amending HIV Drugs

T2 - A Novel Small-Molecule Approach to Target Lupus Anti-DNA Antibodies

AU - Vanpatten, Sonya

AU - Sun, Shan

AU - He, Mingzhu

AU - Cheng, Kai Fan

AU - Altiti, Ahmad

AU - Papatheodorou, Angelos

AU - Kowal, Czeslawa

AU - Jeganathan, Venkatesh

AU - Crawford, James M.

AU - Bloom, Ona

AU - Volpe, Bruce T.

AU - Grant, Christian

AU - Meurice, Nathalie

AU - Coleman, Thomas R.

AU - Diamond, Betty

AU - Al-Abed, Yousef

PY - 2016/10/13

Y1 - 2016/10/13

N2 - Systemic lupus erythematosus is an autoimmune disease that can affect numerous tissues and is characterized by the production of nuclear antigen-directed autoantibodies (e.g., anti-dsDNA). Using a combination of virtual and ELISA-based screens, we made the intriguing discovery that several HIV-protease inhibitors can function as decoy antigens to specifically inhibit the binding of anti-dsDNA antibodies to target antigens such as dsDNA and pentapeptide DWEYS. Computational modeling revealed that HIV-protease inhibitors comprised structural features present in DWEYS and predicted that analogues containing more flexible backbones would possess preferred binding characteristics. To address this, we reduced the internal amide backbone to improve flexibility, producing new small-molecule decoy antigens, which neutralize anti-dsDNA antibodies in vitro, in situ, and in vivo. Pharmacokinetic and SLE model studies demonstrated that peptidomimetic FISLE-412,1 a reduced HIV protease inhibitor analogue, was well-tolerated, altered serum reactivity to DWEYS, reduced glomeruli IgG deposition, preserved kidney histology, and delayed SLE onset in NZB/W F1 mice.

AB - Systemic lupus erythematosus is an autoimmune disease that can affect numerous tissues and is characterized by the production of nuclear antigen-directed autoantibodies (e.g., anti-dsDNA). Using a combination of virtual and ELISA-based screens, we made the intriguing discovery that several HIV-protease inhibitors can function as decoy antigens to specifically inhibit the binding of anti-dsDNA antibodies to target antigens such as dsDNA and pentapeptide DWEYS. Computational modeling revealed that HIV-protease inhibitors comprised structural features present in DWEYS and predicted that analogues containing more flexible backbones would possess preferred binding characteristics. To address this, we reduced the internal amide backbone to improve flexibility, producing new small-molecule decoy antigens, which neutralize anti-dsDNA antibodies in vitro, in situ, and in vivo. Pharmacokinetic and SLE model studies demonstrated that peptidomimetic FISLE-412,1 a reduced HIV protease inhibitor analogue, was well-tolerated, altered serum reactivity to DWEYS, reduced glomeruli IgG deposition, preserved kidney histology, and delayed SLE onset in NZB/W F1 mice.

UR - http://www.scopus.com/inward/record.url?scp=84991288347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991288347&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b00694

DO - 10.1021/acs.jmedchem.6b00694

M3 - Article

VL - 59

SP - 8859

EP - 8867

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 19

ER -